Expert Ratings for Nektar Therapeutics
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter:
Benzinga’s Daily Brief On Trending Tickers For April 18, 2022: Casa Systems, Twitter, DiDi Global, And More
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
Nektar, Bristol Myers Jointly Decide To End Development Program For Nektar’s BEMPEG In Combo With Bristol’s Opdivo
Nektar Therapeutics (NASDAQ:NKTR) and Bristol Myers Squibb (NYSE:BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.
What 4 Analyst Ratings Have To Say About Nektar Therapeutics
Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter:
Where Nektar Therapeutics Stands With Analysts
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter:
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
MDNA: No Read-Through for MDNA11 Based on Nektar Failure…
By David Bautz, PhD
NASDAQ:MDNA
READ THE FULL MDNA RESEARCH REPORT
10 Biggest Price Target Changes For Tuesday
Wells Fargo cut the price target on Coupa Software Incorporated (NYSE: LPI) from $190 to $80. Laredo Petroleum shares fell 29.8% to $63.10 in pre-market trading.